Key result
Macrolides may suppress myocarditis, cardiac rejection, and ischemia by altering inflammatory factors and MMPs.
Macrolide antibiotics may offer cardioprotective effects by modulating matrix metalloproteinases and preventing adverse tissue remodeling, though clinical trial results remain controversial.
Answers are grounded in this paper and cite their sources.
May suggest macrolide cardioprotection; leaves open confirmation in randomized trials before any clinical consideration.
Macrolide antibiotics are broadly used for the treatment of various microbial infections. However, they are also known to have multiple biologic effects, such as alteration of inflammatory factors and matrix metalloproteinases (MMPs). Because of controversial results in clinical trials, the effects of macrolides on cardiovascular diseases are still to be elucidated. It has been reported that MMP activity is upregulated in various cardiovascular diseases, such as myocarditis, cardiac transplant rejection and myocardial infarction. However, little is known about the effects of macrolides on cardiovascular diseases. We have reported that clarithromycin suppressed the development of myocarditis, cardiac rejection and myocardial ischemia using animal models. In this article, we reviewed the roles of MMPs in cardiovascular diseases and the effects of macrolides on the prevention of adverse tissue remodeling.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2011) conducted a review in Cardiovascular diseases. Macrolide antibiotics was evaluated. Macrolide antibiotics may suppress the development of myocarditis, cardiac rejection, and myocardial ischemia by altering inflammatory factors and matrix metalloproteinases.
Synapse has enriched 10 related papers. Consider them for comparative context: